The risk of an acute attack of angle-closure glaucoma during the treatment with modern antidepressant drugs
Abstract
Despite the differences in the chemical structure and pharmacological properties, the risk group for the occurrence of an acute attack of angle-closure glaucoma includes the majority of modern antidepressants. The possible mechanisms of influence of these psychotropic drugs on the intraocular pressure are discussed.
About the Authors
T. V. Romanova
I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
T. M. Bukatina
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
N. Yu. Velts
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
E. Yu. Pasternak
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
A. S. Kazakov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
M. A. Darmostukova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
R. N. Alyautdin
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
B. K. Romanov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
References
1. Summary Safety Review — Antidepressants. [Internet]. 2016 [cited 2016 Aug 16]. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/reviewsexamens/antidepress-eng.php.
2. Lai SM, Gangwani R. Medication-induced acute angle closure attack. Hong Kong Med J. 2012; 18: 139–43.
3. Patel KH, Javitt JC, Tielsch JM, et al. Incidence of acute angle-closure glaucoma after pharmacologic mydriasis. Am J Ophthalmol. 1995; 120: 709–17.
4. Tan GS, Wong CY, Wong TY, et al. Is routine pupil dilation safe among Asian patients with diabetes? Invest Ophthalmol Vis Sci. 2009; 50: 4110–3.
5. Lieberman E, Stoudemire A. Use of tricyclic antidepressantsin patients with glaucoma: assessment and appropriate precautions. Psychosomatics 1987; 28: 145–8.
6. Ritch R, Krupin T, Henry C, et al. Oral imipramine and acute angle closure glaucoma. Arch Ophthalmol. 1994; 112: 67–8.
7. Lowe RF. Amitriptyline and glaucoma. Med J Aust 1966; 2: 509–10.
8. Costagliola C, Parmeggiani F, Sebastiani A. SSRIs andintraocular pressure modifications: evidence, therapeutic implications and possible mechanisms. CNS Drugs 2004; 18: 475–84.
9. Patel OP, Simon MR. Oculogyric dystonic reaction to escitalopram with features of anaphylaxis including response to epinephrine. Int Arch Allergy Immunol. 2006; 140: 27–9.
10. Costagliola C, Mastropasqua L, Capone D, et al. Effect of fluoxetine on intraocular pressure in the rabbit. Exp Eye Res. 2000; 70: 551–5.
11. Koshechkin KA, Gladkaya EV, Kondrateva YaYu. Validation of pharmaceutical information systems: general provisions. Scientific Centre for Expert Evaluation of Medicinal Products Bulletin 2015; (1): 49–52 (in Russian).
Review
For citations:
Romanova T.V., Bukatina T.M., Velts N.Yu., Pasternak E.Yu., Kazakov A.S., Darmostukova M.A., Alyautdin R.N., Romanov B.K. The risk of an acute attack of angle-closure glaucoma during the treatment with modern antidepressant drugs. Safety and Risk of Pharmacotherapy. 2016;(4):27-30. (In Russ.)
Views:
1885
Email this article 